Free weekly newsletter

Get the free weekly executive digest

The new leadership moves, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.

Weekly Digest

New leadership moves, summarized for you

Straight to Inbox

No login, no app to check — it comes to you

Leadership Trends

See who's moving and how much in your market

No credit card required Weekly executive digest

Next Rna Therapeutics Appoints Jesse Smith As Chief Scientific Officer (CSO)

PRIVATESep 26, 2024•over 1 year ago

Position

Chief Scientific Officer

Company

NextRNA Therapeutics

Jesse Smith

BostonBiotechnology

Description

NextRNA Therapeutics has appointed Dr. Jesse Smith as Chief Scientific Officer (CSO). Dr Smith brings over 20 years of drug discovery and development experience with a focus on advancing targeted small molecule therapies disrupting lncRNA-RBP interactions.

Company Information

Company

NextRNA Therapeutics

Location

40 Guest St.

Boston, Massachusetts, United States

About

NextRNA Therapeutics, Inc. is a Boston-based biotechnology company leading the next revolution of RNA-directed therapeutics. Our focus is on identifying and drugging long non-coding RNAs (lncRNAs) with small molecules in oncology and neuroscience. Our proprietary computational engine, combined with deep lncRNA biology expertise and strong drug discovery capabilities, positions us well to unlock the therapeutic value of lncRNAs, a vast and promising target space. NextRNA has assembled an experienced team of industry leaders, biology and chemistry experts, and drug developers, all driven by a common passion for working together and having an impact on science and patients.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence

Strategic

ML-powered predictions for NextRNA Therapeutics's next move

Learn about Strategic plan

Executive Insights

Based on hiring data

New executive impact window

87% of new executives make significant technology decisions within first 100 days

Budget influence

C-level executives control 73% of technology spending decisions

Transformation catalyst

65% of new senior hires launch digital transformation initiatives

Vendor review timeline

New executives typically review existing vendors within 6 months